Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

01.04.25 18:10 Uhr

Werte in diesem Artikel
Aktien

22,69 EUR -0,11 EUR -0,48%

Indizes

PKT PKT

16.801,5 PKT -51,1 PKT -0,30%

2.736,5 PKT 15,6 PKT 0,57%

5.671,0 PKT 37,9 PKT 0,67%

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Pfizer (PFE), which belongs to the Zacks Large Cap Pharmaceuticals industry.This drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 48.44%.For the last reported quarter, Pfizer came out with earnings of $0.63 per share versus the Zacks Consensus Estimate of $0.48 per share, representing a surprise of 31.25%. For the previous quarter, the company was expected to post earnings of $0.64 per share and it actually produced earnings of $1.06 per share, delivering a surprise of 65.63%.Price and EPS SurpriseFor Pfizer, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank.Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.Pfizer currently has an Earnings ESP of +21.50%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on April 29, 2025.When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss.Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Pfizer und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Pfizer

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Pfizer

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Pfizer Inc.

Wer­bung

Analysen zu Pfizer Inc.

DatumRatingAnalyst
07.03.2025Pfizer HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
05.02.2025Pfizer KaufenDZ BANK
05.02.2025Pfizer BuyGoldman Sachs Group Inc.
05.02.2025Pfizer NeutralUBS AG
05.02.2025Pfizer NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
05.02.2025Pfizer KaufenDZ BANK
05.02.2025Pfizer BuyGoldman Sachs Group Inc.
04.02.2025Pfizer BuyJefferies & Company Inc.
17.12.2024Pfizer BuyJefferies & Company Inc.
30.10.2024Pfizer BuyGoldman Sachs Group Inc.
DatumRatingAnalyst
07.03.2025Pfizer HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
05.02.2025Pfizer NeutralUBS AG
05.02.2025Pfizer NeutralJP Morgan Chase & Co.
04.02.2025Pfizer NeutralUBS AG
04.02.2025Pfizer NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
03.05.2018Pfizer VerkaufenDZ BANK
16.05.2017Pfizer SellCitigroup Corp.
27.11.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)
28.08.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)
10.01.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Pfizer Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen